Additionally, IL-22, which is functionally associated with IL-23R signaling, has been implicated in promoting Sorafenib resistance in HCC through STAT3 activation, leading to enhanced tumor cell survival and decreased apoptosis. Here, IL22 is linked to neoplasm.